Home Boston Scientific

Boston Scientific

April 24, 2019: LOTUS Edge ™ Aortic Valve System FDA Approval

The LOTUS Edge valve system is the only FDA-approved aortic valve that gives physicians the option to reposition and completely recapture the valve once it has been fully deployed. It also features a braided valve frame and an adaptive seal that minimizes paravalvular regurgitation or leaking (PVL) by conforming to the patient's native aortic valve.

Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device Receives CE Mark

3/13/19: The WATCHMAN device has been implanted in more than 75,000 patients worldwide and we are pleased that this next-generation technology has been granted European regulatory approval so that we can offer it to patients and clinicians throughout Europe.

Boston Scientific Launches Spectra WaveWriter™ Spinal Cord Stimulator System in Europe

1/31/19: Spectra WaveWriter™ Spinal Cord Stimulator allows physicians & patients to specifically target one area of pain, or multiple areas, with one or both types of therapy to address individual needs.

Boston Scientific Exercises Option to Acquire Millipede, Inc.

12/27/18: Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system.

Boston Scientific Announces Recommended Offer to Acquire BTG plc

11/20/18: The transaction has been unanimously approved by the boards of directors of Boston Scientific and BTG. Under the terms of the transaction, holders of BTG's common shares would receive cash consideration of 840 pence per share. The total cash consideration for 100% of BTG's equity is approximately £3.3B, or U.S.$4.2B. The transaction is intended to be effected by way of an English court-sanctioned scheme of arrangement, and is expected to close in the first half of 2019, subject to receipt of required regulatory approvals and the approval of BTG's shareholders and the U.K. court.

Eluvia™ Drug-Eluting Vascular Stent System Receives FDA Approval

9/24/18: The Eluvia stent utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel for a one-year timeframe, designed to prevent tissue regrowth that might otherwise block the stented artery.

LithoVue Empower™ Retrieval Deployment Device is Launched by Boston Scientific

9/21/18: “The LithoVue Empower Device is a unique tool that can improve ureteroscopic stone treatment as it puts the process of stone manipulation entirely into the hands of the surgeon,” said Dr. Brian Matlaga, the Stephens Professor of Urology at Johns Hopkins Medical Institutions and director of stone disease, James Buchanan Brady Urological Institute and presenting author of the data. “Ultimately, the LithoVue Empower Device introduces a novel efficiency into ureteroscopic stone surgery, as it makes it simpler for the urologist to pick up and move a stone – a historic source of frustration for this procedure."

Claret Medical to be Acquired by Boston Scientific

7/20/18: "Through the development and commercialization of the Sentinel System, Claret Medical has successfully introduced a new layer of safety and peace of mind for physicians and their patients undergoing TAVR procedures," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific.

Boston Scientific to Acquire Cryterion Medical, Inc.

7/5/18: Company to expand atrial fibrillation ablation therapy offerings with innovative cryoballoon platform.

Positive Late-Breaking Data From The INTREPID Study

4/24/18: This is the first and only prospective, double-blind, randomized, sham-controlled, multi-center study of deep brain stimulation (DBS) for advanced, levodopa-responsive Parkinson's disease (PD) in the United States.

Vercise™ Deep Brain Stimulation System Receives U.S. FDA Approval

12/12/17: Boston Scientific Corporation oday announced that it has received approval from the U.S. Food and Drug Administration for the Vercise™ Deep Brain Stimulation System.

Boston Scientific Delays Commercialization on LOTUS Edge™ Aortic Valve System – Company Analyzing and Implementing Necessary Modifications

11/29/17: Boston Scientific (NYSE: BSX) announces a delay to previously communicated timelines for commercialization of the LOTUS Edge™ Aortic Valve System* in Europe and the U.S.

Five-year Follow-up Data Demonstrate the WATCHMAN™ Left Atrial Appendage Closure Device Provides Stroke Risk Reduction Comparable to Warfarin Therapy

Boston Scientific (NYSE: BSX) announced final 5 YR outcomes data from the PREVAIL study of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical trial session at the 29th Transcatheter Cardiovascular Therapeutics, the annual scientific symposium of the Cardiovascular Research Foundation, in Denver.

Desiree Ralls-Morrison General Counsel and Corporate Secretary Appointed by Boston Scientific

HOME Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Desiree Ralls-Morrison as senior vice president, general counsel and corporate secretary....

Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System

  Industry's First MR-Conditional Directional DBS System with Stimulation Visualization Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS)...

Boston Scientific Closes Symetis Acquisition

Acquisition Expands Company's Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease Boston Scientific Corporation (NYSE: BSX) today announced the...

Positive European Registry Results For WATCHMAN™ Left Atrial Appendage Closure Device

Largest Prospective Study of the WATCHMAN Device Presented as Late-Breaking Trial at Heart Rhythm 2017 Boston Scientific (NYSE: BSX) today announced positive safety and efficacy...

New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints

New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints Analyses Evaluated the Impact of Ethnicity, Gender and...

Boston Scientific S-ICD System Demonstrates Positive Clinical Outcomes in the Largest Prospective Study of ‘Real-World’ Patients

Late-Breaker Data Presented at Heart Rhythm 2017 Boston Scientific (NYSE: BSX) today announced results from the U.S. post-market approval study evaluating 'real-world' patients implanted with...

Pivotal Data From REPRISE III and EWOLUTION Among Four Late-breaking Clinical Trials to be Presented at EuroPCR 2017

All events are listed in Central European Summer Time (CEST) and take place at the Palais des Congrès. For additional details about Boston Scientific...

Boston Scientific Announces Agreement to Acquire Symetis

  Acquisition Will Expand Treatments for Patients with Valvular Heart Disease and Strengthen Company's Position in Structural Heart Globally Boston Scientific Corporation (NYSE: BSX) today announced...

NICE Recommends Boston Scientific CRT-D Devices Powered By EnduraLife™ Battery Technology For Treatment Of Heart Failure

BOSTON SCIENTIFIC:  The National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac...

Must Read

New Study Validates Rigorous Safety Measures Needed To Reduce Mercury Exposure During Dental Amalgam Filling Removal

"For decades, our non-profit organization has been concerned about this issue and collected research about amalgam fillings, all of which contain approximately 50% mercury, a known neurotoxin," explains IAOMT President Michael Rehme, DDS, NMD.  "Based on this science, we have strongly recommended that safety measures be enacted for dental procedures involving these silver-colored fillings, and we have also intensely advocated for the end of dental amalgam usage."